Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Eleven brokerages give Bicycle Therapeutics a consensus recommendation of Moderate Buy (1 sell, 4 hold, 5 buy, 1 strong buy) and the average 12‑month price objective is $14.38, even as several firms have recently cut their targets.
• Bicycle reported Q1 EPS of ($0.29) and revenue of $47.96M, beating estimates by wide margins, but the company remains unprofitable with a negative net margin of 301.66% and analysts forecast -1.86 EPS for the year.
• Shares trade around $4.73 (50‑day $5.04, 200‑day $6.23) with a 12‑month low of $4.24 and market cap ≈$330M; insiders recently sold stock (CEO sold 5,967 shares) and institutional investors own about 86.15% of the float.

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $14.3750.

Several research firms have recently commented on BCYC. Truist Financial set a $8.00 price objective on shares of Bicycle Therapeutics in a report on Tuesday, March 17th. Citizens Jmp dropped their price objective on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a "market outperform" rating on the stock in a report on Wednesday, March 18th. Oppenheimer dropped their price objective on shares of Bicycle Therapeutics from $44.00 to $36.00 and set an "outperform" rating on the stock in a report on Wednesday, March 18th. Jefferies Financial Group raised shares of Bicycle Therapeutics to a "strong-buy" rating in a report on Tuesday, February 17th. Finally, Morgan Stanley dropped their price objective on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 8th.

Bicycle Therapeutics Price Performance

BCYC stock opened at $4.73 on Thursday. The firm's fifty day simple moving average is $5.04 and its 200-day simple moving average is $6.23. The company has a market capitalization of $329.71 million, a P/E ratio of -1.50 and a beta of 1.65. Bicycle Therapeutics has a 12 month low of $4.24 and a 12 month high of $9.55.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.71. The business had revenue of $47.96 million for the quarter, compared to the consensus estimate of $7.08 million. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 33.21%. As a group, sell-side analysts forecast that Bicycle Therapeutics will post -1.86 earnings per share for the current year.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 5,967 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total transaction of $29,297.97. Following the sale, the chief executive officer directly owned 613,029 shares of the company's stock, valued at approximately $3,009,972.39. This represents a 0.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 9,992 shares of company stock worth $49,363 over the last quarter. Corporate insiders own 8.50% of the company's stock.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Assetmark Inc. boosted its holdings in Bicycle Therapeutics by 74.9% during the third quarter. Assetmark Inc. now owns 3,625 shares of the company's stock worth $28,000 after buying an additional 1,552 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in Bicycle Therapeutics by 234.2% during the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company's stock worth $33,000 after buying an additional 3,262 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC purchased a new stake in Bicycle Therapeutics during the fourth quarter worth $71,000. Ausdal Financial Partners Inc. purchased a new stake in Bicycle Therapeutics during the second quarter worth $70,000. Finally, Vontobel Holding Ltd. purchased a new stake in Bicycle Therapeutics during the fourth quarter worth $71,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.